<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39427014</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Impaired SARS-CoV-2-specific responses via activated T follicular helper cells in immunocompromised kidney transplant recipients.</ArticleTitle><Pagination><StartPage>24571</StartPage><MedlinePgn>24571</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24571</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76251-x</ELocationID><Abstract><AbstractText>Activated T follicular helper (aTfh) cells are likely important in host immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination. We characterized the immune responses of aTfh cells to the second (D2) and third (booster; D3) doses of an mRNA vaccine in the peripheral blood of 40 kidney transplant recipients (KTRs) and 17 healthy control volunteers (HCs). A significant increase in SARS-CoV-2-specific IgG antibody was seen after D3 in the KTRs; nonetheless, the levels after D2 and D3 were significantly lower than in the HCs. After D2, dramatic increases in activated CD45RA<sup>-</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup>PD1<sup>+</sup> circulating Tfh (acTfh) cells were observed in the HCs, as well as the seropositive patients among the KTRs, when compared with the seronegative patients among the KTRs. Unlike the HCs, KTRs had less prominent immune responses, including the acTfh and T cells that produce interferon gamma, tumor necrosis factor alpha, and interleukin 21. In addition, the increase in acTfh cells was significantly associated with anti-IgG antibody levels after D3. These results indicate impaired SARS-CoV-2-specific responses via acTfh cells in KTRs, and they suggest that acTfh cells in peripheral blood may play an important role in antibody maintenance following SARS-CoV-2 mRNA vaccination.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4959-6290</Identifier><AffiliationInfo><Affiliation>Department of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. ytomita@tokai.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uehara</LastName><ForeName>Saeko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terada</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Virology, Division of Host Defense Mechanism, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Michio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23K15460</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000084522" MajorTopicYN="Y">T Follicular Helper Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066027" MajorTopicYN="Y">Transplant Recipients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Activated T follicular helper cells</Keyword><Keyword MajorTopicYN="N">IL21</Keyword><Keyword MajorTopicYN="N">Immune system</Keyword><Keyword MajorTopicYN="N">Kidney transplantation</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccination</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39427014</ArticleId><ArticleId IdType="pmc">PMC11490627</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76251-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76251-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Takiguchi, S. et al. Immunological imprint on peripheral blood in kidney transplant recipients after two doses of SARS-CoV-2 mRNA vaccination in Japan. Front. Med. (Lausanne) 9, 999374. 10.3389/fmed.2022.999374 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9553995</ArticleId><ArticleId IdType="pubmed">36250073</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita, Y., Uehara, S., Terada, M., Yamamoto, N. &amp; Nakamura, M. Effects of anti-SARS-CoV-2 vaccination in living kidney transplant recipients prior to transplantation. Clin. Exp. Nephrol. 10.1007/s10157-024-02535-1 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38969932</ArticleId></ArticleIdList></Reference><Reference><Citation>Danthu, C. et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J. Am. Soc. Nephrol. 32, 2153–2158. 10.1681/ASN.2021040490 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8729854</ArticleId><ArticleId IdType="pubmed">34135083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin, D. et al. SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination: a prospective cohort study. Clin. Kidney J. 15, 992–998. 10.1093/ckj/sfac031 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903319</ArticleId><ArticleId IdType="pubmed">35498878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rincon-Arevalo, H. et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. 10.1126/sciimmunol.abj1031 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34131023</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrowska, M. et al. Local and systemic immunity are impaired in end-stage-renal-disease patients treated with hemodialysis, peritoneal dialysis and kidney transplant recipients immunized with BNT162b2 Pfizer-BioNTech SARS-CoV-2 vaccine. Front. Immunol. 13, 832924. 10.3389/fimmu.2022.832924 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9354587</ArticleId><ArticleId IdType="pubmed">35935974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale, J. S. et al. Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. Immunity 38, 805–817. 10.1016/j.immuni.2013.02.020 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3741679</ArticleId><ArticleId IdType="pubmed">23583644</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529–542. 10.1016/j.immuni.2014.10.004 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223692</ArticleId><ArticleId IdType="pubmed">25367570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169-183.e117. 10.1016/j.cell.2020.11.029 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682481</ArticleId><ArticleId IdType="pubmed">33296701</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ploeg, K. et al. TNF-α. Cell Rep. Med. 3, 100640. 10.1016/j.xcrm.2022.100640 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9061140</ArticleId><ArticleId IdType="pubmed">35588734</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita, R. et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34, 108–121. 10.1016/j.immuni.2010.12.012 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046815</ArticleId><ArticleId IdType="pubmed">21215658</ArticleId></ArticleIdList></Reference><Reference><Citation>He, J. et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 39, 770–781. 10.1016/j.immuni.2013.09.007 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24138884</ArticleId></ArticleIdList></Reference><Reference><Citation>Herati, R. S. et al. Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells. Sci. Immunol. 10.1126/sciimmunol.aag2152 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469419</ArticleId><ArticleId IdType="pubmed">28620653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer, K. et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell 185, 1008-1024.e1015. 10.1016/j.cell.2022.01.027 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8808747</ArticleId><ArticleId IdType="pubmed">35202565</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, H. T follicular helper cells in space-time. Nat. Rev. Immunol. 16, 612–625. 10.1038/nri.2016.94 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27573485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, C. S. &amp; Phan, T. G. Here, there and everywhere: T follicular helper cells on the move. Immunology 152, 382–387. 10.1111/imm.12793 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5629422</ArticleId><ArticleId IdType="pubmed">28704588</ArticleId></ArticleIdList></Reference><Reference><Citation>Förster, R., Emrich, T., Kremmer, E. &amp; Lipp, M. Expression of the G-protein–coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood 84, 830–840 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7913842</ArticleId></ArticleIdList></Reference><Reference><Citation>Förster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037–1047. 10.1016/s0092-8674(00)81798-5 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8978608</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiba, H. et al. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J. Immunol. 175, 2340–2348. 10.4049/jimmunol.175.4.2340 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16081804</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes, N. M. et al. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J. Immunol. 179, 5099–5108. 10.4049/jimmunol.179.8.5099 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17911595</ArticleId></ArticleIdList></Reference><Reference><Citation>La Muraglia, G. M., Wagener, M. E., Ford, M. L. &amp; Badell, I. R. Circulating T follicular helper cells are a biomarker of humoral alloreactivity and predict donor-specific antibody formation after transplantation. Am. J. Transplant. 10.1111/ajt.15517 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7193899</ArticleId><ArticleId IdType="pubmed">31250973</ArticleId></ArticleIdList></Reference><Reference><Citation>de Graav, G. N. et al. Follicular T helper cells and humoral reactivity in kidney transplant patients. Clin. Exp. Immunol. 180, 329–340. 10.1111/cei.12576 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408167</ArticleId><ArticleId IdType="pubmed">25557528</ArticleId></ArticleIdList></Reference><Reference><Citation>Danger, R. et al. CXCR5. Front. Immunol. 10, 2071. 10.3389/fimmu.2019.02071 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6746839</ArticleId><ArticleId IdType="pubmed">31552030</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit, A. et al. Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J. Exp. Med. 214, 2139–2152. 10.1084/jem.20161794 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502430</ArticleId><ArticleId IdType="pubmed">28637884</ArticleId></ArticleIdList></Reference><Reference><Citation>Herati, R. S. et al. Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J. Immunol. 193, 3528–3537. 10.4049/jimmunol.1302503 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4170011</ArticleId><ArticleId IdType="pubmed">25172499</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannella, M. et al. Evaluation of the kinetics of antibody response to COVID-19 vaccine in solid organ transplant recipients: The prospective multicenter ORCHESTRA cohort. Microorganisms 10.3390/microorganisms10051021 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147204</ArticleId><ArticleId IdType="pubmed">35630462</ArticleId></ArticleIdList></Reference><Reference><Citation>Alejo, J. L. et al. Six-month antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients. Transplantation 106, e109–e110. 10.1097/TP.0000000000003975 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667681</ArticleId><ArticleId IdType="pubmed">34711780</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky, B. J. et al. Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients. Transplantation 105, e137–e138. 10.1097/TP.0000000000003863 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8484034</ArticleId><ArticleId IdType="pubmed">34241987</ArticleId></ArticleIdList></Reference><Reference><Citation>Charmetant, X. et al. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Sci. Transl. Med. 14, eabl6141. 10.1126/scitranslmed.abl6141 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939774</ArticleId><ArticleId IdType="pubmed">35103481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirillo, L. et al. Response to third dose of vaccine against SARS-CoV-2 in adolescent and young adult kidney transplant recipients. Transplantation 106, e386–e387. 10.1097/TP.0000000000004199 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35581690</ArticleId></ArticleIdList></Reference><Reference><Citation>Malahe, S. R. K. et al. The role of interleukin-21 in COVID-19 vaccine-induced B cell-mediated immune responses in patients with kidney disease and kidney transplant recipients. Am. J. Transplant. 10.1016/j.ajt.2023.05.025 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10234364</ArticleId><ArticleId IdType="pubmed">37270109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita, Y. et al. CD45RA-CD25highCD127-CD4+ activated regulatory T cells are correlated with de novo donor-specific anti-HLA antibody formation after kidney transplantation in standard immunosuppression. Int. Immunopharmacol. 97, 107661. 10.1016/j.intimp.2021.107661 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33887579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>